Trial Profile
A phase II, biomarker study using digital PCR method in EGFR mutated, advanced lung adenocarcinoma patients treated with afatinib. WJOG8114LTR
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 03 Apr 2018 Status changed from active, no longer recruiting to completed.
- 18 Oct 2017 Update results presented at the 18th World Conference on Lung Cancer.
- 20 Apr 2016 Trial design presented at the 107th Annual Meeting of the American Association for Cancer Research